Gleevec

(Imatinib)

ApprovedProtein / enzyme

Imatinib is used to treat certain types of cancer, particularly chronic myeloid leukemia (a blood cancer) and gastrointestinal stromal tumors. It works by blocking proteins that help cancer cells grow and divide.[2] Gleevec is currently approved and in use across 54 indications[4].[1]

Gleevec is one of 771 small molecule programs targeting Myeloid Leukemia. It is currently in Approved.

Indications

428

Total Trials

Active Trials

770

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Myeloid LeukemiaCompleted

Chronic Myelogenous LeukemiaCompleted

Stem Cell TransplantNot yet recruiting

Clear Cell Renal CarcinomaApproved

FibrosarcomaApproved

Desmoid-Type FibromatosisApproved

Thymic CarcinomaApproved

Systemic SclerodermaApproved

Intestinal CancerApproved

Head and Neck Squamous Cell CarcinomaApproved

Myeloid LeukemiaApproved

Completed

Chronic Myelogenous LeukemiaApproved

Completed

Stem Cell TransplantPhase 2

Not yet recruiting

Clear Cell Renal CarcinomaApproved

Approved

FibrosarcomaApproved

Approved

Desmoid-Type FibromatosisApproved

Approved

Thymic CarcinomaApproved

Approved

Systemic SclerodermaApproved

Approved

Intestinal CancerApproved

Approved

Head and Neck Squamous Cell CarcinomaApproved

Approved

Showing 10 of 54 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Gleevec

Novartis

Approved

8 2

Zolymbus

AbbVie

Preclinical

1 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Duragesic-100

CCephalon

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 7

Duragesic

CCephalon

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Combination Therapy

NCT07022743

Phase 1Active, not recruiting

GIST

NCT05245968

Post-ApprovalRecruiting

Children

NCT03844360

Q1 2027

Phase 2Active, not recruiting

Hypereosinophilic Syndrome

NCT00044304

Q3 2027

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT03589326

Q1 2028

Phase 3Recruiting

Pneumonia

NCT02735707

Clinical

Trials by Indication[1]

Myeloid Leukemia26 trials

Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan

Completed·HHikma Pharmaceuticals LLC··NCT02977312·91 enrolled

Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy

Completed·UUniversità degli Studi di Brescia·Phase 2·NCT00858806·78 enrolled

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Active, not recruiting·SSWOG Cancer Research Network·Phase 2·NCT03654768·81 enrolled

Show 23 more trials

A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia

Completed·UUppsala University·Phase 2·NCT01227356·112 enrolled

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

Completed· Novartis logo

Novartis·Phase 2·NCT00171158·260 enrolled

Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 1/2·NCT00028847·60 enrolled

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01751425·8 enrolled

Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia

Unknown status·LLynn McMahon·Phase 2·NCT01227135·66 enrolled

Glivec in Pediatric Chronic Myeloid Leukemia (CML)

Completed·PPoitiers University Hospital·Phase 4·NCT00845221·44 enrolled

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Completed· Pfizer logo

Pfizer··NCT05286528·1,484 enrolled

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01593254·262 enrolled

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00362466·3 enrolled

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00481247·547 enrolled

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 4·NCT05367765·2,400 enrolled

Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

Completed·HHikma Pharmaceuticals LLC··NCT03454503·173 enrolled

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Unknown status·CCttq·Phase 4·NCT02317159·90 enrolled

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00103844·150 enrolled

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT01188889

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Completed· Novartis logo

Novartis·Phase 2·NCT03578367·104 enrolled

Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia

Completed·NNorwegian University of Science and Technology·Phase 2·NCT00852566·46 enrolled

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00320190·52 enrolled

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Completed·IIl-Yang Pharm. Co., Ltd.·Phase 3·NCT01511289·242 enrolled

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto··NCT01475110·19 enrolled

TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study

Completed·UUniversity of Pisa··NCT01860456·412 enrolled

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Completed· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 2·NCT04126681·144 enrolled

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Unknown status·CCentral European Leukemia Study Group·Phase 3·NCT00327262·240 enrolled

Acute Lymphoblastic Leukemia18 trials

Ma-Spore ALL 2020 Study

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06336395·500 enrolled

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Unknown status·PPETHEMA Foundation·Phase 4·NCT01491763·70 enrolled

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01319981·31 enrolled

Show 15 more trials

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01383447·2 enrolled

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00036738·28 enrolled

Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01312818·2 enrolled

Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·N/A·NCT00049569·126 enrolled

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Active, not recruiting· Takeda logo

Takeda·Phase 3·NCT03589326·245 enrolled

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

Completed·JJapan Adult Leukemia Study Group·Phase 2·NCT00130195·100 enrolled

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 2·NCT00199186

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Completed·MMassachusetts General Hospital·Phase 2·NCT00973752·30 enrolled

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Completed·GGoethe University·Phase 3·NCT02881086·1,023 enrolled

Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT01025505·40 enrolled

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00022737·220 enrolled

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02894645·500 enrolled

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00081133

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Withdrawn·UUniversity of Washington·Phase 2·NCT02538926

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·UUniversity College, London··NCT01085617

Gastrointestinal Stromal Tumor14 trials

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT04933669·122 enrolled

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00009906·748 enrolled

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00324987·12 enrolled

Show 11 more trials

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02257541·16 enrolled

5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

Recruiting·—·Phase 2·NCT05385549·35 enrolled

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate

Completed· Novartis logo

Novartis·Phase 4·NCT00510354·28 enrolled

Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 2·NCT00764595·5 enrolled

Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

Completed· Novartis logo

Novartis·Phase 4·NCT00171977·64 enrolled

Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)

Unknown status·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT04138381·30 enrolled

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg

Terminated· Novartis logo

Novartis·Phase 3·NCT00751036·94 enrolled

A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors

Completed· Novartis logo

Novartis·Phase 2·NCT00940563·135 enrolled

Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

Completed· Novartis logo

Novartis·Phase 2·NCT00237172·72 enrolled

Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

Recruiting·UUniversity of California, San Diego·Phase 1·NCT07171203·18 enrolled

Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index

Unknown status·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT02576080·80 enrolled

Chronic Myelogenous Leukemia13 trials

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00110058·40 enrolled

Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia

Unknown status·MMeng Li·Phase 2·NCT02687425·20 enrolled

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Completed· Novartis logo

Novartis·Phase 3·NCT00471497·846 enrolled

Show 10 more trials

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054431·80 enrolled

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Completed· Novartis logo

Novartis·Phase 3·NCT00006343

STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

Completed· Novartis logo

Novartis·Phase 2·NCT00006053

STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia

Completed· Novartis logo

Novartis·Phase 2·NCT00006052

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

Completed· Novartis logo

Novartis·Phase 3·NCT00237120·100 enrolled

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Completed· Novartis logo

Novartis·Phase 3·NCT02272777·225 enrolled

Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Active, not recruiting·CCentre Leon Berard·Phase 2·NCT04070443·170 enrolled

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00015834·46 enrolled

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

Completed· Novartis logo

Novartis·Phase 2·NCT00006475

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

Completed· Novartis logo

Novartis·Phase 1/2·NCT00093639

Treatment8 trials

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

Active, not recruiting·HHeikki Joensuu·Phase 3·NCT02413736·255 enrolled

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

Completed· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 3·NCT02204644·400 enrolled

Entacapone Combination With Imatinib for Treatment of GIST

Completed·XXiangya Hospital of Central South University·Phase 1·NCT04006769·5 enrolled

Show 5 more trials

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

Unknown status·NNational Research Center for Hematology, Russia·Phase 2·NCT04578847·100 enrolled

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Not yet recruiting·PPeking University Shenzhen Hospital·Phase 2·NCT06692491·200 enrolled

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Terminated·AAB Science·Phase 3·NCT00812240·335 enrolled

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting·PPETHEMA Foundation··NCT06175702·150 enrolled

Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT

Completed·—·Phase 3·NCT01151852·81 enrolled

92 more indications

Melanoma4 trials

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

Completed·—·Phase 2·NCT00424515·24 enrolled

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT01782508·40 enrolled

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00074308·40 enrolled

Show 1 more trial

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00470470·30 enrolled

Chemotherapy3 trials

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02611492·265 enrolled

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT05071482·39 enrolled

Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

Recruiting·GGoethe University·Phase 2·NCT06061094·220 enrolled

Small Cell Lung Cancer3 trials

Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·UUniversity Health Network, Toronto·Phase 1·NCT00052494·9 enrolled

Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00052949·91 enrolled

Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193349·60 enrolled

Hypereosinophilic syndrome3 trials

Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

Completed·NNorthern Italy Leukemia Group·Phase 2·NCT00787384·25 enrolled

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00044304·70 enrolled

A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome

Terminated· Novartis logo

Novartis·Phase 2·NCT00171860·24 enrolled

Pulmonary Arterial Hypertension3 trials

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

Completed· Novartis logo

Novartis·Phase 3·NCT01392469·21 enrolled

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Terminated· Novartis logo

Novartis·Phase 3·NCT01392495·17 enrolled

Positioning Imatinib for Pulmonary Arterial Hypertension

Unknown status·IImperial College London·Phase 2·NCT04416750·17 enrolled

Pneumonia2 trials

The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

Unknown status·—·Phase 3·NCT04422678·30 enrolled

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting·UUMC Utrecht·Phase 3·NCT02735707·20,000 enrolled

Leukemia2 trials

High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)

Completed·NNantes University Hospital·Phase 2·NCT00707408·15 enrolled

Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.

Unknown status·HHospices Civils de Lyon·Phase 2·NCT00149136·30 enrolled

Scleroderma2 trials

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Unknown status·AAzienda Ospedaliera Universitaria Policlinico·Phase 2·NCT00573326·30 enrolled

Efficacy and Safety of Imatinib in Scleroderma

Completed·UUniversity Hospital, Bordeaux·Phase 2·NCT00479934·28 enrolled

Unresectable2 trials

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Unknown status·—·Phase 2·NCT01541709·23 enrolled

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00068783·40 enrolled

Non-Small Cell Lung Cancer2 trials

Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer

Terminated·RRutgers, The State University of New Jersey·Phase 2·NCT00323362·17 enrolled

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01083589·22 enrolled

Fibrosis2 trials

Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec

Completed·UUniversity of Aarhus·Phase 3·NCT00981942·10 enrolled

Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

Completed·MMassachusetts General Hospital·Phase 2·NCT00677092·12 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host

Completed·UUniversity Hospital, Lille·Phase 2·NCT02891395·65 enrolled

The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia

Unknown status·TThe University of Hong Kong·Phase 2·NCT03241199·15 enrolled

Gastric Cancer2 trials

A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00068380·17 enrolled

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Completed·SSamsung Medical Center·Phase 2·NCT03170180·66 enrolled

Dermatofibrosarcoma Protuberans2 trials

Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00085475·17 enrolled

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00084630·40 enrolled

CML2 trials

Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients

Completed·UUniversity of Milano Bicocca·Phase 4·NCT01578213·112 enrolled

Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 3·NCT03515018·60 enrolled

Asthma2 trials

Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Completed·—·Phase 2·NCT01097694·176 enrolled

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT04129931·395 enrolled

Tyrosine Kinase Inhibitors2 trials

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Completed·UUNC Lineberger Comprehensive Cancer Center··NCT03885830·45 enrolled

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT01188278·173 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

Completed· Novartis logo

Novartis·Phase 3·NCT01275196·267 enrolled

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

Recruiting·—·Phase 2·NCT04626024·100 enrolled

Relapsed or Refractory2 trials

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Terminated·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 1/2·NCT02462538·3 enrolled

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Unknown status·SSamsung Medical Center·Phase 2·NCT02638428·90 enrolled

Chronic Graft Versus Host Disease1 trial

A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease

Completed·DDavid Miklos·Phase 1·NCT00760981·15 enrolled

Adjuvant1 trial

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00415857·5 enrolled

Thyroid Carcinoma1 trial

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00115739·11 enrolled

COVID-191 trial

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Unknown status·SSunnybrook Health Sciences Centre·Phase 3·NCT04330690·2,900 enrolled

Children1 trial

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Recruiting·WWei Zhao·Phase 4·NCT03844360·1,500 enrolled

Malaria1 trial

Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites

Unknown status·NNurex S.r.l.·Phase 2·NCT03697668·50 enrolled

Chronic Myelomonocytic Leukemia1 trial

Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00079313·7 enrolled

Stem Cell Transplant1 trial

Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

Not yet recruiting·TThe University of Hong Kong·Phase 2·NCT07493408·45 enrolled

Trial1 trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Plasmodium falciparum malaria1 trial

Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria

Completed·HHuLow·Phase 1·NCT02614404·15 enrolled

Ovarian Cancer1 trial

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

Completed·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 2·NCT00928642·8 enrolled

Colorectal Cancer1 trial

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Terminated· Novartis logo

Novartis·Phase 1·NCT01271166·10 enrolled

Head and Neck Squamous Cell Cancer1 trial

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00485485·7 enrolled

MPA1 trial

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

Completed·IInhibikase Therapeutics·Phase 1·NCT05623774·64 enrolled

Hematologic Cancer1 trial

Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

Completed·VVirginia Commonwealth University·Phase 1·NCT00064285·22 enrolled

Brain Tumor1 trial

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00049127·64 enrolled

Interaction1 trial

Drug-drug Interaction Study With Metformin and Imatinib

Completed·UUniversity of California, San Francisco·Phase 1·NCT01404715·11 enrolled

Meningioma1 trial

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Completed·—·Phase 2·NCT00354913·21 enrolled

Refractory1 trial

Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children

Terminated·SSeoul National University Hospital·Phase 2·NCT01898377·9 enrolled

Myelofibrosis1 trial

Imatinib Mesylate in Treating Patients With Myelofibrosis

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00039416·18 enrolled

Kaposi's sarcoma1 trial

Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00090987·30 enrolled

Prostate Cancer1 trial

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00500110·39 enrolled

Preoperative1 trial

Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST

Not yet recruiting·FFujian Medical University Union Hospital·Phase 3·NCT05970900·23 enrolled

Tics1 trial

Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers

Completed·JJan Beumer·Phase 1·NCT00732784·11 enrolled

Metastatic Colorectal Cancer1 trial

New Individualized Therapy Trial for Metastatic Colorectal Cancer

Completed·IInova Health Care Services·Phase 1/2·NCT00867334·10 enrolled

Glioma1 trial

Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00021229·85 enrolled

Pleural Mesothelioma1 trial

Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

Completed·IIstituto Clinico Humanitas·Phase 2·NCT02303899·22 enrolled

Patients With Advanced Solid Tumors1 trial

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

Completed·HHerbert Hurwitz·Phase 1·NCT00253565·25 enrolled

Primary Peritoneal Cancer1 trial

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00036751·40 enrolled

Acute Myeloid Leukemia1 trial

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

Withdrawn·UUniversity of Cincinnati·Phase 2·NCT00594555·20 enrolled

Plexiform Neurofibroma1 trial

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Terminated·SSt. Justine's Hospital·Phase 2·NCT02177825·5 enrolled

Advanced Cancer1 trial

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00025415·60 enrolled

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00180921·30 enrolled

Philadelphia Chromosome Positive CML1 trial

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

Completed· Pfizer logo

Pfizer·Phase 3·NCT00574873·502 enrolled

Injury1 trial

A Study to Investigate the Effects of Imatinib on Pulmonary Vascular Dysfunction in a Human Model of Lung Injury

Completed·EExvastat Ltd.·Phase 1·NCT03328117·47 enrolled

Newly Diagnosed1 trial

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 3·NCT06051409·350 enrolled

Sepsis1 trial

Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis

Not yet recruiting·BBelfast Health and Social Care Trust·Phase 1/2·NCT06626984·65 enrolled

Adult ALL1 trial

ALL Adult Consortium Trial: Adult ALL Trial

Completed·—·Phase 2·NCT00476190·112 enrolled

Combination Therapy1 trial

Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy

Active, not recruiting·OObafemi Awolowo University·Phase 2·NCT07022743·75 enrolled

Breast Cancer1 trial

Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193180·37 enrolled

Fibromatosis1 trial

Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

Withdrawn·MMedPacto, Inc.·Phase 2·NCT06219733

Bone Marrow Transplantation1 trial

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Completed· Incyte logo

Incyte·Phase 3·NCT03112603·330 enrolled

Solid Tumor1 trial

Imatinib and Trametinib for KRAS-mutated Solid Tumor

Recruiting·—·Phase 1·NCT06962254·10 enrolled

Adult1 trial

Study in Adult Ph-positive ALL

Unknown status·—·Phase 2·NCT04688983·180 enrolled

Side Effects1 trial

Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment

Completed·IImperial College London··NCT00632255·88 enrolled

Hematologic Malignancies1 trial

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT02352558·15 enrolled

Ocular Melanoma1 trial

Imatinib in Adult Patients With Metastatic Ocular Melanoma

Terminated·CCentre Oscar Lambret·Phase 2·NCT00421317·13 enrolled

HIE1 trial

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Active, not recruiting·SSarit Assouline·Phase 3·NCT05413915·164 enrolled

Ph+ ALL1 trial

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Completed· Novartis logo

Novartis·Phase 1·NCT02081378·326 enrolled

Intestinal Cancer1 trial

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study

Unknown status·SSun Yat-sen University·N/A·NCT02013089·50 enrolled

Rheumatoid Arthritis1 trial

A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.

Completed· Novartis logo

Novartis·Phase 2·NCT00154336·50 enrolled

Systemic Sclerosis1 trial

A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis

Completed·UUniversity of California, Los Angeles·Phase 1/2·NCT00512902·20 enrolled

GIST1 trial

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

Active, not recruiting· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 1·NCT05245968·78 enrolled

Clinical Efficacy and Safety1 trial

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Unknown status·SSamsung Medical Center·Phase 2·NCT02461849·14 enrolled

Sickle Cell Disease1 trial

Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease

Withdrawn·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT01568645

Metastatic Melanoma1 trial

A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma

Terminated·YYale University·Phase 2·NCT00402662·3 enrolled

Seasonal Allergic Rhinitis1 trial

Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen

Completed· Novartis logo

Novartis·Phase 1/2·NCT00426179·30 enrolled

Pancreatic Cancer1 trial

Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer

Completed·RRoyal Marsden NHS Foundation Trust·Phase 1·NCT01048320·36 enrolled

Chordoma1 trial

Efficacy and Safety of Imatinib in Chordoma

Completed· Novartis logo

Novartis·Phase 2·NCT00150072·55 enrolled

Metastatic Solid Tumors1 trial

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

Completed·UUniversity of California, San Francisco·Phase 1·NCT00390156·35 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Terminated·NNational Taiwan University Hospital·Phase 2·NCT03343600·5 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00376467·105 enrolled

Targeted Therapy1 trial

Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy

Terminated·UUMC Utrecht·Phase 2·NCT02685046·5 enrolled

Gastrointestinal Stromal Tumour1 trial

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)

Unknown status·AAustralasian Gastro-Intestinal Trials Group·Phase 2·NCT02365441·78 enrolled

Spinal Cord Injury1 trial

Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study

Unknown status·PProfessor Mikael Svensson, MD PhD·Phase 2·NCT02363361·10 enrolled

Quality of Life1 trial

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Completed·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 3·NCT02326311·229 enrolled

Chondrosarcoma1 trial

Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

Completed·IItalian Sarcoma Group·Phase 2·NCT00928525·35 enrolled

Malignant Peripheral Nerve Sheath Tumor1 trial

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Terminated· Novartis logo

Novartis·Phase 2/3·NCT00427583·11 enrolled

Systemic Mastocytosis1 trial

Imatinib in KIT-negative Systemic Mastocytosis

Completed·HHospital Virgen de la Salud·Phase 4·NCT01297777·10 enrolled

Tyrosine Kinase Inhibitor1 trial

A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs

Completed·—·Phase 2·NCT02712112·51 enrolled

Unspecified5 trials

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

Completed·UUniversity of Pittsburgh·Phase 1·NCT00446004·15 enrolled

An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years

Terminated·PProf. Dr. Nikolas von Bubnoff·Phase 3·NCT02174445·14 enrolled

Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib

Completed· Novartis logo

Novartis·Phase 1·NCT00422825·16 enrolled

Show 2 more trials

Exploring the Molecular Mechanism Based on KIT Mutation

Unknown status·XXijing Hospital··NCT05895942·190 enrolled

Effect of Food on Bioavailability of Modified Release Formulations of Imatinib

Completed· Novartis logo

Novartis·Phase 1·NCT00420043·32 enrolled

Regulatory

FDA Approval Timeline[5]

May 10, 2001

GLEEVEC

NDA NDA021335

Apr 18, 2003

GLEEVEC

NDA NDA021588

Nov 22, 2024

IMKELDI

NDA NDA219097

Sources

References

[1]
ClinicalTrials.gov — 428 trial records for Imatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Gleevec drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Imatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Imatinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219097). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Gleevec. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Bcr/abl Fusion Protein Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Platelet-Derived Growth Factor Receptor Beta Inhibitor; Tyrosine-Protein Kinase ABL Inhibitor[3]
Modality: Protein / enzyme[3]
Highest Phase: Approved[1]
Company: Novartis

Patent Landscape[6]

Patent Cliff

Apr 27, 2040

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11957681Apr 27, 2040

Gleevec

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q1 2028

Trials by Indication[1]

Myeloid Leukemia26 trials

Acute Lymphoblastic Leukemia18 trials

Gastrointestinal Stromal Tumor14 trials

Chronic Myelogenous Leukemia13 trials

Treatment8 trials

Melanoma4 trials

Chemotherapy3 trials

Small Cell Lung Cancer3 trials

Hypereosinophilic syndrome3 trials

Pulmonary Arterial Hypertension3 trials

Pneumonia2 trials

Leukemia2 trials

Scleroderma2 trials

Unresectable2 trials

Non-Small Cell Lung Cancer2 trials

Fibrosis2 trials

Efficacy and Safety2 trials

Gastric Cancer2 trials

Dermatofibrosarcoma Protuberans2 trials

CML2 trials

Asthma2 trials

Tyrosine Kinase Inhibitors2 trials

Safety and Efficacy2 trials

Relapsed or Refractory2 trials

Chronic Graft Versus Host Disease1 trial

Adjuvant1 trial

Thyroid Carcinoma1 trial

COVID-191 trial

Children1 trial

Malaria1 trial

Chronic Myelomonocytic Leukemia1 trial

Stem Cell Transplant1 trial

Trial1 trial

Plasmodium falciparum malaria1 trial

Ovarian Cancer1 trial

Colorectal Cancer1 trial

Head and Neck Squamous Cell Cancer1 trial

MPA1 trial

Hematologic Cancer1 trial

Brain Tumor1 trial

Interaction1 trial

Meningioma1 trial

Refractory1 trial

Myelofibrosis1 trial

Kaposi's sarcoma1 trial

Prostate Cancer1 trial

Preoperative1 trial

Tics1 trial

Metastatic Colorectal Cancer1 trial

Glioma1 trial

Pleural Mesothelioma1 trial

Patients With Advanced Solid Tumors1 trial

Primary Peritoneal Cancer1 trial

Acute Myeloid Leukemia1 trial

Plexiform Neurofibroma1 trial

Advanced Cancer1 trial

Concentration1 trial

Clinical Trial1 trial

Adenoid Cystic Carcinoma1 trial

Philadelphia Chromosome Positive CML1 trial

Injury1 trial

Newly Diagnosed1 trial

Sepsis1 trial

Adult ALL1 trial

Combination Therapy1 trial

Breast Cancer1 trial

Fibromatosis1 trial

Bone Marrow Transplantation1 trial

Solid Tumor1 trial

Adult1 trial

Side Effects1 trial